# Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency

> **NCT05317806** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Indiana Hemophilia &Thrombosis Center, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Plasminogen Activator Inhibitor-1 Deficiency
- Cardiac Fibrosis

## Interventions

- **DRUG:** Metformin Extended Release Oral Tablet

## Key facts

- **NCT ID:** NCT05317806
- **Lead sponsor:** Indiana Hemophilia &Thrombosis Center, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05317806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05317806, "Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05317806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*